
    
      Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to
      evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal
      mucosa with lesions caused by HPV. All the patients included in the study will be Randomized
      (1:1:1) to Arm A (Papilocare schedule A), Arm B (Papilocare schedule B) and Arm C (usual
      clinical practice -without treatment-). Selection period of 1 month, followed by
      randomization and 6 months of treatment followed by a period of another 6 months without
      treatment. Patients will visit the site into a total of 5 visits throughout the study.
    
  